ABT has said it would like to add to its diagnostics segment. However, even 11 years after Cologuard FDA approval, EXAS is essentially a breakeven operation. Cost synergies from a buyout could presumably make EXAS’ operations accretive to ABT’s earnings, but not hugely so (IMO).
Meanwhile, ABT is -3% today, which is a very big daily move for this stock.
Market Data 
Markets 
AI
